LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.94 -0.51

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.93

Max

2.03

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-24M

-154K

Pardavimai

-32M

19M

P/E

Sektoriaus vid.

3.98

35.293

Pelno marža

-0.825

Darbuotojai

119

EBITDA

-24M

-939K

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+144.39% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-48M

328M

Ankstesnė atidarymo kaina

2.45

Ankstesnė uždarymo kaina

1.94

Naujienos nuotaikos

By Acuity

50%

50%

346 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-17 23:01; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025-09-17 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025-09-17 21:59; UTC

Uždarbis

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025-09-17 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-09-17 23:39; UTC

Rinkos pokalbiai

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025-09-17 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025-09-17 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025-09-17 21:00; UTC

Uždarbis

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025-09-17 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025-09-17 19:07; UTC

Rinkos pokalbiai

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025-09-17 18:43; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025-09-17 18:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025-09-17 18:20; UTC

Rinkos pokalbiai

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025-09-17 18:14; UTC

Rinkos pokalbiai

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025-09-17 17:59; UTC

Rinkos pokalbiai

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025-09-17 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025-09-17 17:06; UTC

Įsigijimai, susijungimai, perėmimai

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025-09-17 16:51; UTC

Uždarbis

Correct: Exor 1H Net Loss -EUR624M

2025-09-17 16:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 16:34; UTC

Rinkos pokalbiai

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025-09-17 16:25; UTC

Uždarbis

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025-09-17 16:23; UTC

Uždarbis

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

144.39% į viršų

12 mėnesių prognozė

Vidutinis 4.79 USD  144.39%

Aukščiausias 7 USD

Žemiausias 3.5 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

346 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat